References
1. Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, Jørgensen JO, Cuneo RC,Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L,Baxter RC, Basset EE, Sönksen PH. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab. 2000 Nov;85(11):4193-200.
2. Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57:411-34. Review.
3. Ribeiro SML, Kehayias JJ. Sarcopenia and the Analysis of Body Composition. Advances in Nutrition. 2014;5(3):260-267.
4. Schoenfeld BJ. The mechanisms of muscle hypertrophy and their application to resistance training. J Strength Cond Res. 2010 Oct;24 (10):2857-72.
5. Stickland NC. Muscle development in the human fetus as exemplified by m.sartorius: a quantitative study. J Anat. 1981 Jun;132(Pt 4):557-79.
6. Antonio J, Gonyea WJ. Skeletal muscle fiber hyperplasia. Med Sci Sports Exerc. 1993 Dec;25(12):1333-45. Review.
7. Fernández AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D.Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest. 2002 Feb;109(3):347-55.
8. Kadi F, Thornell LE. Training affects myosin heavy chain phenotype in the trapezius muscle of women. Histochem Cell Biol. 1999 Jul;112(1):73-8.
9. D’Antona G, Lanfranconi F, Pellegrino MA, Brocca L, Adami R, Rossi R, Moro G, Miotti D, Canepari M, Bottinelli R.Skeletal muscle hypertrophy and structure and function of skeletal muscle fibres in male body builders. J Physiol. 2006 Feb 1;570(Pt 3):611-27.
10. Cohen-Gadol AA, Liu JK, Laws ER Jr. Cushing’s first case of transsphenoidal surgery: the launch of the pituitary surgery era. J Neurosurg. 2005 Sep;103(3):570-4.
11. Li CH, Evans HM. THE ISOLATION OF PITUITARY GROWTH HORMONE. Science. 1944 Mar 3;99(2566):183-4.
12. SALMON WD Jr, DAUGHADAY WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957 Jun;49(6):825-36.
13. Daughaday WH, Reeder C. Synchronous activation of DNA synthesis in hypophysectomized rat cartilage by growth hormone. J Lab Clin Med. 1966 Sep;68(3):357-68.
14. Garland JT, Lottes ME, Kozak S, Daughaday WH. Stimulation of DNA synthesis in isolated chondrocytes by sulfation factor. Endocrinology. 1972 Apr;90(4):1086-90.
15. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ.Somatomedin: proposed designation for sulphation factor. Nature. 1972 Jan 14;235(5333):107.
16. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001 Feb;22(1):53-74. Review.
17. D’Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol. 1980 Mar 15;75(2):315-28.
18. Han VK, Lund PK, Lee DC, D’Ercole AJ. Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. J Clin Endocrinol Metab. 1988 Feb;66(2):422-9.
19. Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science. 1982 Jun 11;216 (4551):1237-9.
20. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987 Nov;8(4):426-38. Review.
21. Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation. 1985;29(3):195-8. Review.
22. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978 Apr 25;253(8):2769-76.
23. Klapper DG, Svoboda ME, Van Wyk JJ. Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology. 1983 Jun;112(6):2215-7.
24. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989 Feb;10(1):68-91. Review.
25. Hintz RL, Liu F. Demonstration of specific plasma protein binding sites for somatomedin. J Clin Endocrinol Metab. 1977 Nov;45(5):988-95.
26. BECK JC, McGARRY EE, DYRENFURTH I, VENNING EH. The metabolic effects of human and monkey growth hormone in man. Ann Intern Med. 1958 Nov;49(5):1090-105.
27. IKKOS D, LUFT R, GEMZELL CA. The effect of human growth hormone in man. Lancet. 1958 Apr 5;1(7023):720-1.
28. RABEN MS, HOLLENBERG CH. Effect of growth hormone on plasma fatty acids. J Clin Invest. 1959 Mar;38(3):484-8. PubMed PMID: 13641397
29. RABEN MS. Growth hormone. 1. Physiologic aspects. N Engl J Med. 1962 Jan 4;266:31-5.
30. RABEN MS. Growth hormone. 2. Clinical use of human growth hormone. N Engl J Med. 1962 Jan 11;266:82-6 concl.
31. ZIERLER KL, RABINOWITZ D. ROLES OF INSULIN AND GROWTH HORMONE, BASED ON STUDIES OF FOREARM METABOLISM IN MAN. Medicine (Baltimore). 1963 Nov;42:385-402.
32. RABINOWITZ D, KLASSEN GA, ZIERLER KL. EFFECT OF HUMAN GROWTH HORMONE ON MUSCLE AND ADIPOSE TISSUE METABOLISM IN THE FOREARM OF MAN. J Clin Invest. 1965 Jan;44:51-61.
33. Fineberg SE, Merimee TJ. Acute metabolic effects of human growth hormone. Diabetes. 1974 Jun;23(6):499-504.
34. Appleby BS, Lu M, Bizzi A, et al. Iatrogenic Creutzfeldt-Jakob Disease from Commercial Cadaveric Human Growth Hormone. Emerging Infectious Diseases. 2013;19(4):682-684. doi:10.3201/eid1904.121504.
35.https://www.gene.com/media/press-releases/4235/1985-10-18/fda-approves-genentechs-drug-to-treat-ch
36. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1-9.
37. Crist DM, Peake GT, Egan PA, Waters DL. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol (1985). 1988 Aug;65(2):579-84.
38. Møller N, Copeland KC, Nair KS. Growth hormone effects on protein metabolism. Endocrinol Metab Clin North Am. 2007 Mar;36(1):89-100. Review.
39. Argetsinger LS, Carter-Su C. Mechanism of signaling by growth hormone receptor. Physiol Rev. 1996 Oct;76(4):1089-107. Review.
40. Hayashi AA, Proud CG. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1647-55.
41. Kostyo JL. Rapid effects of growth hormone on amino acid transport and protein synthesis. Ann N Y Acad Sci. 1968 Feb 5;148(2):389-407.
42. Cameron CM, Kostyo JL, Adamafio NA, Brostedt P, Roos P, Skottner A, Forsman A, Fryklund L, Skoog B. The acute effects of growth hormone on amino acid transport and protein synthesis are due to its insulin-like action. Endocrinology. 1988 Feb;122(2):471-4.
43. Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology. 1997 Oct;138(10):4301-7.
44. Costoya JA, Finidori J, Moutoussamy S, Seãris R, Devesa J, Arce VM. Activation of growth hormone receptor delivers an antiapoptotic signal: evidence for a role of Akt in this pathway. Endocrinology. 1999 Dec;140(12):5937-43.
45. Copeland KC, Nair KS. Acute growth hormone effects on amino acid and lipid metabolism. J Clin Endocrinol Metab. 1994 May;78(5):1040-7.
46. Umpleby AM, Boroujerdi MA, Brown PM, Carson ER, Sönksen PH. The effect of metabolic control on leucine metabolism in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1986 Mar;29(3):131-41.
47. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest. 1990 Jul;86(1):265-72.
48. Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 1992 Mar;262(3 Pt 1):E261-7.
49. Zachwieja JJ, Bier DM, Yarasheski KE. Growth hormone administration in older adults: effects on albumin synthesis. Am J Physiol. 1994 Jun;266(6 Pt 1):E840-4.
50. Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol. 1995 Feb;268(2 Pt 1):E268-76.
51. Healy ML, Gibney J, Russell-Jones DL, Pentecost C, Croos P, Sönksen PH, Umpleby AM. High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab. 2003 Nov;88(11):5221-6.
52. Giannoulis MG, Jackson N, Shojaee-Moradie F, Nair KS, Sonksen PH, Martin FC, Umpleby AM. The effects of growth hormone and/or testosterone on whole body protein kinetics and skeletal muscle gene expression in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2008 Aug;93(8):3066-74.
53. Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol. 1991 Mar;260(3 Pt 1):E499-504.
54. Fryburg DA, Louard RJ, Gerow KE, Gelfand RA, Barrett EJ. Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin’s antiproteolytic action in humans. Diabetes. 1992 Apr;41(4):424-9.
55. Fryburg DA, Barrett EJ. Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism. 1993 Sep;42(9):1223-7.
56. Nørrelund H, Nair KS, Jørgensen JO, Christiansen JS, Møller N. The protein-retaining effects of growth hormone during fasting involve inhibition of muscle-protein breakdown. Diabetes. 2001 Jan;50(1):96-104.
57. Manson JM, Wilmore DW. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery. 1986 Aug;100(2):188-97.
58. Clemmons DR, Snyder DK, Williams R, Underwood LE. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab. 1987 May;64(5):878-83.
59. Snyder DK, Clemmons DR, Underwood LE. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J Clin Endocrinol Metab. 1988 Jul;67(1):54-61.
60. Tagliaferri M, Scacchi M, Pincelli AI, Berselli ME, Silvestri P, Montesano A, Ortolani S, Dubini A, Cavagnini F. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women. Int J Obes Relat Metab Disord. 1998 Sep;22(9):836-41.
61. Nørrelund H, Børglum J, Jørgensen JO, Richelsen B, Møller N, Nair KS, Christiansen JS. Effects of growth hormone administration on protein dynamics andsubstrate metabolism during 4 weeks of dietary restriction in obese women. Clin Endocrinol (Oxf). 2000 Mar;52(3):305-12.
62. Lundeberg S, Belfrage M, Wernerman J, von der Decken A, Thunell S, Vinnars E. Growth hormone improves muscle protein metabolism and whole body nitrogen economy in man during a hyponitrogenous diet. Metabolism. 1991 Mar;40(3):315-22
63. Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol. 1994 Aug;267(2 Pt 1):E331-6.
64. Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB, Shojaee-Moradie F, Hopkins KD, Jackson NC, Kelly JM, Jones RH, Sönksen PH. Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Physiol. 1994 Oct;267(4 Pt 1):E591-8.
65. Jacob R, Hu X, Niederstock D, Hasan S, McNulty PH, Sherwin RS, Young LH. IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids. Am J Physiol. 1996 Jan;270(1 Pt 1):E60-6.
66. Buijs MM, Romijn JA, Burggraaf J, De Kam ML, Cohen AF, Frölich M, Stellaard F, Meinders AE, Pijl H. Growth hormone blunts protein oxidation and promotes protein turnover to a similar extent in abdominally obese and normal-weight women. J Clin Endocrinol Metab. 2002 Dec;87(12):5668-74.
67. Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK. Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E266-71.
68. Le Roith D, Scavo L, Butler A. What is the role of circulating IGF-I? Trends Endocrinol Metab. 2001 Mar;12(2):48-52. Review.
69. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res. 2005 Feb;15(1):19-27. Review.
70. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44.
71. Muhammad A, van der Lely AJ, Neggers SJ. Review of current and emerging treatment options in acromegaly. Neth J Med. 2015 Oct;73(8):362-7. Review.
72. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001 Jan 1;229(1):141-62.
73. Waters MJ. The growth hormone receptor. Growth Horm IGF Res. 2016 Jun;28:6-10.
74. Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion – preliminary report. Growth Horm IGF Res. 2008 Oct;18(5):434-8.
75. Sharara FI. Value of growth hormone in ovulation induction? Fertil Steril. 1996 Jun;65(6):1259-61.
76. Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2009 Nov-Dec;15(6):613-22.
77. Russell SM, Spencer EM. Local injections of human or rat growth hormone or of purified human somatomedin-C stimulate unilateral tibial epiphyseal growth in hypophysectomized rats. Endocrinology. 1985 Jun;116(6):2563-7.
78. Schlechter NL, Russell SM, Greenberg S, Spencer EM, Nicoll CS. A direct growth effect of growth hormone in rat hindlimb shown by arterial infusion. Am J Physiol. 1986 Mar;250(3 Pt 1):E231-5.
79. Isaksson OG, Ohlsson C, Nilsson A, Isgaard J, Lindahl A. Regulation of cartilage growth by growth hormone and insulin-like growth factor I. Pediatr Nephrol. 1991 Jul;5(4):451-3. Review.
80. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998 Feb;19(1):55-79. Review.
81. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol. 2004 Feb;180(2):247-55.
82. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, LeRoith D. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 2009 Mar;23(3):709-19.
83. Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009 Aug;30(5):494-535.
84. Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, Pende M. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7315-20.
85. Wakelam MJ. The fusion of myoblasts. Biochem J. 1985 May 15;228(1):1-12. Review.
86. Pfäffle RW, Blankenstein O, Wüller S, Kentrup H. Combined pituitary hormone deficiency: role of Pit-1 and Prop-1. Acta Paediatr Suppl. 1999 Dec;88(433):33-41. Review.
87. Hemchand K, Anuradha K, Neeti S, Vaman K, Roland P, Werner B, Sharmila B. Entire prophet of Pit-1 (PROP-1) gene deletion in an Indian girl with combined pituitary hormone deficiencies. J Pediatr Endocrinol Metab. 2011;24(7-8):579-80.
88. Waters MJ, Shang CA, Behncken SN, Tam SP, Li H, Shen B, Lobie PE. Growth hormone as a cytokine. Clin Exp Pharmacol Physiol. 1999 Oct;26(10):760-4. Review.
89. Jansson JO, Edén S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev. 1985 Spring;6(2):128-50. Review.
90. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998 Dec;19(6):717-97. Review.
91. Hartman ML, Faria AC, Vance ML, Johnson ML, Thorner MO, Veldhuis JD. Temporal structure of in vivo growth hormone secretory events in humans. Am J Physiol. 1991 Jan;260(1 Pt 1):E101-10.
92. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079-90.
93. Parker DC, Sassin JF, Mace JW, Gotlin RW, Rossman LG. Human growth hormone release during sleep: electroencephalographic correlation. J Clin Endocrinol Metab. 1969 Jun;29(6):871-4.
94. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, Thorner MO. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988 Apr;81(4):968-75.
95. Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I, DeMott-Friberg R, Bermann M, Barkan AL. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest. 1998 Jul 1;102(1):153-64.
96. Jessup SK, Dimaraki EV, Symons KV, Barkan AL. Sexual dimorphism of growth hormone (GH) regulation in humans: endogenous GH-releasing hormone maintains basal GH in women but not in men. J Clin Endocrinol Metab. 2003 Oct;88(10):4776-80.
97. Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am. 2007 Mar;36(1):37-55. Review.
98. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999 Apr;79(2):511-607. Review.
99. Murray RA, Maheshwari HG, Russell EJ, Baumann G. Pituitary hypoplasia in patients with a mutation in the growth hormone-releasing hormone receptor gene. AJNR Am J Neuroradiol. 2000 Apr;21(4):685-9.
100. Murray PG, Higham CE, Clayton PE. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-GH axis: the past 60 years. J Endocrinol. 2015 Aug;226(2):T123-40.
101. Russell-Aulet M, Dimaraki EV, Jaffe CA, DeMott-Friberg R, Barkan AL. Aging-related growth hormone (GH) decrease is a selective hypothalamic GH-releasing hormone pulse amplitude mediated phenomenon. J Gerontol A Biol Sci Med Sci. 2001 Feb;56(2):M124-9
102. Dimaraki EV, Jaffe CA, Demott-Friberg R, Russell-Aulet M, Bowers CY, Marbach P, Barkan AL. Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator. Am J Physiol Endocrinol Metab. 2001 Mar;280(3):E489-95.
103. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 1991 Nov;12(4):424-49. Review.
104. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010 Feb;20(1):1-7. doi: 10.1016/j.ghir.2009.09.002. Epub 2009 Oct 1. Review.
105. Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001 Aug;12(6):252-7. Review.
106. Baumann G. Growth hormone binding protein. The soluble growth hormone receptor. Minerva Endocrinol. 2002 Dec;27(4):265-76. Review.
107. Bairoch A, Apweiler R. The SWISS-PROT protein sequence data bank and its new supplement TREMBL. Nucleic Acids Res. 1996 Jan 1;24(1):21-5.
108. Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev. 1991 Aug;12(3):235-51. Review.
109. Vikman K, Carlsson B, Billig H, Edén S. Expression and regulation of growth hormone (GH) receptor messenger ribonucleic acid (mRNA) in rat adipose tissue, adipocytes, and adipocyte precursor cells: GH regulation of GH receptor mRNA. Endocrinology. 1991 Sep;129(3):1155-61.
110. Zou L, Menon RK, Sperling MA. Induction of mRNAs for the growth hormone receptor gene during mouse 3T3-L1 preadipocyte differentiation. Metabolism. 1997 Jan;46(1):114-8.
111. Leung KC, Waters MJ, Markus I, Baumbach WR, Ho KK. Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: a novel mechanism of growth hormone receptor regulation. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11381-6.
112. Birzniece V, Sata A, Ho KK. Growth hormone receptor modulators. Rev Endocr Metab Disord. 2009 Jun;10(2):145-56.
113. Sawada T, Arai D, Jing X, Miyajima M, Frank SJ, Sakaguchi K. Molecular interactions of EphA4, growth hormone receptor, Janus kinase 2, and signal transducer and activator of transcription 5B. PLoS One. 2017 Jul 7;12(7):e0180785.
114. Brooks AJ, Dai W, O’Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, Gomez GA, Alexandrov K, Wilson IA, Doxastakis M, Mark AE, Waters MJ. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014 May 16;344(6185):1249783.
115. Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Dynamic analysis of GH receptor conformational changes by split luciferase complementation. Mol Endocrinol. 2014 Nov;28(11):1807-19.
116. Waters MJ, Brooks AJ. JAK2 activation by growth hormone and other cytokines. Biochem J. 2015 Feb 15;466(1):1-11.
117. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005 Sep;12(9):814-21. Epub 2005 Aug 21.
118. Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006 Dec;7(4):225-35. Review.
119. Carter-Su C, Schwartz J, Smit LS. Molecular mechanism of growth hormone action. Annu Rev Physiol. 1996;58:187-207. Review.
120. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol. 2010 Sep;6(9):515-25.
121. Cohen P. Overview of the IGF-I system. Horm Res. 2006;65 Suppl 1:3-8. Epub 2006 Mar 2. Review.
122. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7324-9.
123. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Molecular Pathology. 2001;54(5):311-316.
124. Wurzburger MI, Prelevic GM, Sönksen PH, Balint-Peric LA, Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab. 1993 Jul;77(1):267-72.
125. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002 Sep;110(6):771-81.
126. D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984 Feb;81(3):935-9.
127. Gosteli-Peter MA, Winterhalter KH, Schmid C, Froesch ER, Zapf J. Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messenger ribonucleic acid levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone. Endocrinology. 1994 Dec;135(6):2558-67.
128. Gunawardane K, Krarup Hansen T, Sandahl Christiansen J, et al. Normal Physiology of Growth Hormone in Adults. [Updated 2015 Nov 12]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
129. Lu C, Lam HN, Menon RK. New members of the insulin family: regulators of metabolism, growth and now … reproduction. Pediatr Res. 2005 May;57(5 Pt 2):70R-73R.
130. Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J, Stannard B, Scavo L, Leroith D. Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev. 2005 Sep;3(1):11-9. Review.
131. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007 Feb;28(1):20-47. Epub 2006 Aug 24. Review.
132. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012 Jun;41(2):425-43, vii-viii.
133. Kim JJ, Accili D. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res. 2002 Apr;12(2):84-90. Review.
134. Shimizu M, Webster C, Morgan DO, Blau HM, Roth RA. Insulin and insulin-like growth factor receptors and responses in cultured human muscle cells. Am J Physiol. 1986 Nov;251(5 Pt 1):E611-5.
135. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001 Nov;86(11):5176-83.
136. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999 Dec;20(6):761-87. Review.
137. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002 Dec;23(6):824-54. Review.
138. Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem. 1993 May 5;268(13):9246-54.
139. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol. 2001 Jul;170(1):63-70. Review.
140. Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol. 2002 Oct;175(1):41-54. Review.
141. LeRoith D. Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab. 1996 Jan;10(1):49-73. Review.
142. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997 Dec;18(6):801-31. Review.
143. Monzavi R, Cohen P. IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab. 2002 Sep;16(3):433-47. Review.
144. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008 Aug;29(5):535-59. Epub 2008 Apr 24. Review.
145. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 2000 Apr;12(2):121-36. Review.
146. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab. 1999 Oct;68(2):161-81. Review.
147. Parker A, Rees C, Clarke J, Busby WH Jr, Clemmons DR. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Mol Biol Cell. 1998 Sep;9(9):2383-92.
148. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008 Jun;154(3):557-68. Review.
149. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995 Feb;16(1):3-34. Review.
150. Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, Goldspink G. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. 2004 Feb 15;555(Pt 1):231-40. Epub 2003 Oct 17.
151. Pfeffer LA, Brisson BK, Lei H, Barton ER. The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell. 2009 Sep;20(17):3810-7.
152. Zabłocka B, Goldspink PH, Goldspink G, Górecki DC. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol (Lausanne). 2012 Nov 1;3:131.
153. Rotwein P. Two insulin-like growth factor I messenger RNAs are expressed in human liver. Proc Natl Acad Sci U S A. 1986 Jan;83(1):77-81.
154. Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA, Cuttitta F. A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8107-11.
155. Barton ER, DeMeo J, Lei H. The insulin-like growth factor (IGF)-I E-peptides are required for isoform-specific gene expression and muscle hypertrophy after local IGF-I production. J Appl Physiol (1985). 2010 May;108(5):1069-76.
156. Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil. 1996 Aug;17(4):487-95.
157. McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol. 1999 Apr 15;516 (Pt 2):583-92.
158. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002 Jul 3;522(1-3):156-60. Erratum in: FEBS Lett. 2006 May 1;580(10):2530.
159. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest. 1981 May;67(5):1361-9.
160. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993 Feb;14(1):20-39. Review.
161. Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons DA, Abbott R, Mulligan T, Johnson ML, Pincus S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 1995 Nov;80(11):3209-22.
162. Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine. 1997 Aug;7(1):41-8. Review.
163. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991 Nov;73(5):1081-8
164. Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc. 1985 Nov;33(11):800-7. Review.
165. Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab. 1999 Oct;84(10):3490-7.
166. Martin FC, Yeo AL, Sonksen PH. Growth hormone secretion in the elderly: aging and the somatopause. Baillieres Clin Endocrinol Metab. 1997 Jul;11(2):223-50. Review.
167. Chertman LS, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2015 May 4]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
168. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013 Aug;27(4):541-55.
169. Duchaine D. Underground steroid handbook. 1. California: HLR Technical Books; 1983. p. 84
170. Sonksen PH. Insulin, growth hormone and sport. J Endocrinol. 2001 Jul;170(1):13-25. Review.
171. Macintyre JG. Growth hormone and athletes. Sports Med. 1987 Mar-Apr;4(2):129-42. Review.
172. Erotokritou-Mulligan I, Holt RI, Sönksen PH. Growth hormone doping: a review. Open Access Journal of Sports Medicine. 2011;2:99-111.
173. Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008 May 20;148(10):747-58. Epub 2008 Mar 17. Review.
174. Birzniece V, Nelson AE, Ho KK. Growth hormone and physical performance. Trends Endocrinol Metab. 2011 May;22(5):171-8. Mar 17. Review.
175. Baumann GP. Growth hormone doping in sports: a critical review of use and detection strategies. Endocr Rev. 2012 Apr;33(2):155-86. Epub 2012 Feb 24. Review.
176. Gibney J, Healy ML, Sönksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev. 2007 Oct;28(6):603-24. Epub 2007 Sep 4. Review.
177. Holt RI, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008 Jun;154(3):542-56. Epub 2008 Mar 31. Review.
178. Barroso O, Mazzoni I, Rabin O. Hormone abuse in sports: the antidoping perspective. Asian J Androl. 2008 May;10(3):391-402.
179. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc. 2010 Jan;42(1):58-66.
180. Meinhardt U, Nelson AE, Hansen JL, Birzniece V, Clifford D, Leung KC, Graham K, Ho KK. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med. 2010 May 4;152(9):568-77.
181. Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost C, Dall R, Rosén T, Jørgensen JO, Cittadini A, Longobardi S, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab. 1999 Oct;84(10):3591-601.
182. Chikani V, Ho KK. Action of GH on skeletal muscle function: molecular and metabolic mechanisms. J Mol Endocrinol. 2013 Dec 19;52(1):R107-23.
183. Lange KH, Larsson B, Flyvbjerg A, Dall R, Bennekou M, Rasmussen MH, Ørskov H, Kjaer M. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab. 2002 Nov;87(11):4966-75.
184. Berggren A, Ehrnborg C, Rosén T, Ellegård L, Bengtsson BA, Caidahl K. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab. 2005 Jun;90(6):3268-73. Epub 2005 Mar 22.
185. Irving BA, Patrie JT, Anderson SM, Watson-Winfield DD, Frick KI, Evans WS, Veldhuis JD, Weltman A. The effects of time following acute growth hormone administration on metabolic and power output measures during acute exercise. J Clin Endocrinol Metab. 2004 Sep;89(9):4298-305. Epub 2004 Aug 24.
186. Graham MR, Baker JS, Evans P, Kicman A, Cowan D, Hullin D, Davies B. Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users. Growth Horm IGF Res. 2007 Jun;17(3):201-9. Epub 2007 Feb 26.
187. Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, Urban RJ, Veldhuis JD. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002 Dec;87(12):5649-57.
188. Blackman MR, Sorkin JD, Münzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O’Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2282-92.
189. Chikani V, Cuneo RC, Hickman I, Ho KK. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf). 2016 Oct;85(4):660-8.
190. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994 Oct;15(5):555-73. Review.
191. Svensson J, Tivesten A, Isgaard J. Growth hormone and the cardiovascular function. Minerva Endocrinol. 2005 Mar;30(1):1-13. Review.
192. Copeland KC, Nair KS. Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab. 1994 Jul;79(1):230-2.
193. Pete G, Hu Y, Walsh M, Sowers J, Dunbar JC. Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats. Proc Soc Exp Biol Med. 1996 Nov;213(2):187-92.
194. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996 May;137(5):1798-803.
195. Crist DM, Peake GT, Egan PA, Waters DL. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol (1985). 1988 Aug;65(2):579-84.
196. Deyssig R, Frisch H, Blum WF, Waldhör T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh). 1993 Apr;128(4):313-8.
197. Yarasheski KE, Zachweija JJ, Angelopoulos TJ, Bier DM. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol (1985). 1993 Jun;74(6):3073-6.
198. Lange KH, Andersen JL, Beyer N, Isaksson F, Larsson B, Rasmussen MH, Juul A, Bülow J, Kjaer M. GH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab. 2002 Feb;87(2):513-23.
199. Ehrnborg C, Ellegård L, Bosaeus I, Bengtsson BA, Rosén T. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin Endocrinol (Oxf). 2005 Apr;62(4):449-57.
200. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990 Jul 5;323(1):1-6.
201. Taaffe DR, Pruitt L, Reim J, Hintz RL, Butterfield G, Hoffman AR, Marcus R. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 1994 Nov;79(5):1361-6.
202. Taaffe DR, Jin IH, Vu TH, Hoffman AR, Marcus R. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab. 1996 Jan;81(1):421-5.
203. Hennessey JV, Chromiak JA, DellaVentura S, Reinert SE, Puhl J, Kiel DP, Rosen CJ, Vandenburgh H, MacLean DB. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc. 2001 Jul;49(7):852-8.
204. West DW, Kujbida GW, Moore DR, Atherton P, Burd NA, Padzik JP, De Lisio M, Tang JE, Parise G, Rennie MJ, Baker SK, Phillips SM. Resistance exercise-induced increases in putative anabolic hormones do not enhance muscle protein synthesis or intracellular signalling in young men. J Physiol. 2009 Nov 1;587(Pt 21):5239-47.
205. West DW, Burd NA, Tang JE, Moore DR, Staples AW, Holwerda AM, Baker SK, Phillips SM. Elevations in ostensibly anabolic hormones with resistance exercise enhance neither training-induced muscle hypertrophy nor strength of the elbow flexors. J Appl Physiol (1985). 2010 Jan;108(1):60-7.
206. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest. 1995 Oct;96(4):1722-9
207. Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL, Hoffman AR. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol. 1997 Jan;272(1 Pt 1):E94-9.
208. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, Friedman L, Yesavage J, Matthias D, Lee S, Marcus R, Hoffman AR. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 2001 Apr;86(4):1496-503.
209. Consitt LA, Saneda A, Saxena G, List EO, Kopchick JJ. Mice overexpressing growth hormone exhibit increased skeletal muscle myostatin and MuRF1 with attenuation of muscle mass. Skelet Muscle. 2017 Sep 4;7(1):17.
210. Wolf E, Wanke R, Schenck E, Hermanns W, Brem G. Effects of growth hormone overproduction on grip strength of transgenic mice. Eur J Endocrinol. 1995 Dec;133(6):735-40.
211. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism. 1990 Feb;39(2):133-7.
212. Blazer-Yost BL, Cox M. Insulin-like growth factor 1 stimulates renal epithelial Na+ transport. Am J Physiol. 1988 Sep;255(3 Pt 1):C413-7.
213. Giordano M, DeFronzo RA. Acute effect of human recombinant insulin-like growth factor I on renal function in humans. Nephron. 1995;71(1):10-5.
214. Ehrnborg C, Lange KH, Dall R, Christiansen JS, Lundberg PA, Baxter RC, Boroujerdi MA, Bengtsson BA, Healey ML, Pentecost C, Longobardi S, Napoli R, Rosén T; GH-2000 Study Group. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test. J Clin Endocrinol Metab. 2003 Jan;88(1):394-401.
215. Doessing S, Heinemeier KM, Holm L, Mackey AL, Schjerling P, Rennie M, Smith K, Reitelseder S, Kappelgaard AM, Rasmussen MH, Flyvbjerg A, Kjaer M. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol. 2010 Jan 15;588(Pt 2):341-51.
216. Boesen AP, Dideriksen K, Couppé C, Magnusson SP, Schjerling P, Boesen M, Kjaer M, Langberg H. Tendon and skeletal muscle matrix gene expression and functional responses to immobilisation and rehabilitation in young males: effect of growth hormone administration. J Physiol. 2013 Dec 1;591(23):6039-52.
217. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf). 1993 Oct;39(4):417-25.
218. Sullivan DH, Carter WJ, Warr WR, Williams LH. Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. J Gerontol A Biol Sci Med Sci. 1998 May;53(3):M183-7.
219. Dickerman RD, Douglas JA, East JW. Bilateral median neuropathy and growth hormone use: a case report. Arch Phys Med Rehabil. 2000 Dec;81(12):1594-5.
220. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, Grunfeld C. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996 Apr 15;124(8):708-16.
221. Zachwieja JJ, Yarasheski KE. Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Phys Ther. 1999 Jan;79(1):76-82. Review.
222. Kishioka Y, Thomas M, Wakamatsu J, Hattori A, Sharma M, Kambadur R, Nishimura T. Decorin enhances the proliferation and differentiation of myogenic cells through suppressing myostatin activity. J Cell Physiol. 2008 Jun;215(3):856-67.
223. Kanzleiter T, Rath M, Görgens SW, Jensen J, Tangen DS, Kolnes AJ, Kolnes KJ, Lee S, Eckel J, Schürmann A, Eckardt K. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem Biophys Res Commun. 2014 Jul 25;450(2):1089-94.
224. Zhang CZ, Li H, Bartold PM, Young WG, Waters MJ. Effect of growth hormone on the distribution of decorin and biglycan during odontogenesis in the rat incisor. J Dent Res. 1995 Oct;74(10):1636-43.
225. Bahl N, Stone G, McLean M, Ho KKY, Birzniece V. Decorin, a growth hormone regulated protein in humans. Eur J Endocrinol. 2017 Nov 14. pii: EJE-17-0844.
226. Short KR, Moller N, Bigelow ML, Coenen-Schimke J, Nair KS. Enhancement of muscle mitochondrial function by growth hormone. J Clin Endocrinol Metab. 2008 Feb;93(2):597-604. Epub 2007 Nov 13.
227. Lange KH, Isaksson F, Juul A, Rasmussen MH, Bülow J, Kjaer M. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E989-96.
228. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev. 2004 Jan;84(1):209-38. Review.
229. Halevy O, Hodik V, Mett A. The effects of growth hormone on avian skeletal muscle satellite cell proliferation and differentiation. Gen Comp Endocrinol. 1996 Jan;101(1):43-52.
230. Kim H, Barton E, Muja N, Yakar S, Pennisi P, Leroith D. Intact insulin and insulin-like growth factor-I receptor signaling is required for growth hormone effects on skeletal muscle growth and function in vivo. Endocrinology. 2005 Apr;146(4):1772-9. Epub 2004 Dec 23.
231. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E197-205. Epub 2003 Apr 1.
232. Ruzicka, L., Wettstein, A. and Kägi, H. (1935), Sexualhormone VIII. Darstellung von Testosteron unter Anwendung gemischter Ester. HCA, 18: 1478–1482.
233. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med. 1984 Nov-Dec;12(6):469-84. Review.
234. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001 Sep;23(9):1355-90. Review.
235. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005 Nov;60(11):1451-7
236. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54. Review.
237. Kadi F, Eriksson A, Holmner S, Thornell LE. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Med Sci Sports Exerc. 1999 Nov;31(11):1528-34.
238. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004 May;7(3):271-7. Review.
239. Eriksson A, Kadi F, Malm C, Thornell LE. Skeletal muscle morphology in power-lifters with and without anabolic steroids. Histochem Cell Biol. 2005 Aug;124(2):167-75.
240. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol. 2008 Jun;154(3):522-8. Epub 2008 Apr 14. Review.
241. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.
242. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S. Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab. 2003 May;284(5):E1009-17.
243. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005 Feb;90(2):678-88. Epub 2004 Nov 23.
244. Kvorning T, Andersen M, Brixen K, Madsen K. Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1325-32. Epub 2006 Jul 25.
245. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E154-64.
246. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996 Jul 4;335(1):1-7.
247. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab. 2004 Oct;89(10):5245-55.
248. Klover P, Chen W, Zhu BM, Hennighausen L. Skeletal muscle growth and fiber composition in mice are regulated through the transcription factors STAT5a/b: linking growth hormone to the androgen receptor. FASEB J. 2009 Sep;23(9):3140-8.
249. Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999 Aug;84(8):2705-11.
250. Kadi F, Bonnerud P, Eriksson A, Thornell LE. The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem Cell Biol. 2000 Jan;113(1):25-9.
251. de Rooy C, Grossmann M, Zajac JD, Cheung AS. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation. Endocr Relat Cancer. 2016 Jan;23(1):R15-26.
252. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996 Oct;81(10):3469-75.
253. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab. 2003 Jan;88(1):358-62.
254. Bauer ER, Daxenberger A, Petri T, Sauerwein H, Meyer HH. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS. 2000 Dec;108(12):838-46.
255. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003 Nov;144(11):5081-8. Epub 2003 Jul 24.
256. Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010 Jun;75(6):377-89.
257. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev. 2005 Dec;26(7):898-915. Epub 2005 Aug 26. Review.
258. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006 Nov 3;127(3):469-80. Review.
259. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology. 2009 Mar;150(3):1259-68.
260. Zhao JX, Hu J, Zhu MJ, Du M. Trenbolone enhances myogenic differentiation by enhancing β-catenin signaling in muscle-derived stem cells of cattle. Domest Anim Endocrinol. 2011 May;40(4):222-9.
261. Armstrong DD, Esser KA. Wnt/beta-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. Am J Physiol Cell Physiol. 2005 Oct;289(4):C853-9. Epub 2005 May 11.
262. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009 Aug;5(8):442-7.
263. Cossu G, Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J. 1999 Dec 15;18(24):6867-72. Review.
264. Buckingham M. Skeletal muscle formation in vertebrates. Curr Opin Genet Dev. 2001 Aug;11(4):440-8. Review.
265. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell. 2003 Jun 27;113(7):841-52.
266. Tincello DG, Saunders PT, Hodgins MB, Simpson NB, Edwards CR, Hargreaves TB, Wu FC. Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome. Clin Endocrinol (Oxf). 1997 Apr;46(4):497-506.
267. Foradori CD, Weiser MJ, Handa RJ. Non-genomic Actions of Androgens. Frontiers in neuroendocrinology. 2008;29(2):169-181.
268. Lucas-Herald AK, Alves-Lopes R, Montezano AC, Ahmed SF, Touyz RM. Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. Clin Sci (Lond). 2017 Jul 1;131(13):1405-1418.
269. Münzer T, Harman SM, Hees P, Shapiro E, Christmas C, Bellantoni MF, Stevens TE, O’Connor KG, Pabst KM, St Clair C, Sorkin JD, Blackman MR. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab. 2001 Aug;86(8):3604-10.
270. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009 Jun;94(6):1991-2001.
271. Illig R, Prader A. Effect of testosterone on growth hormone secretion in patients with anorchia and delayed puberty. J Clin Endocrinol Metab. 1970 May;30(5):615-8.
272. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, Woitge HW, Blum WF, Wüster C, Haack D, Ziegler R. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. J Clin Endocrinol Metab. 1996 Jul;81(7):2534-40.
273. Erfurth EM, Hagmar LE, Sääf M, Hall K. Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young and middle-aged men. Clin Endocrinol (Oxf). 1996 Jun;44(6):659-64.
274. van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren L. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. J Clin Endocrinol Metab. 1996 Jun;81(6):2227-32.
275. Veldhuis JD, Keenan DM, Mielke K, Miles JM, Bowers CY. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Eur J Endocrinol. 2005 Oct;153(4):577-86.
276. Lewis MI, Fournier M, Storer TW, Bhasin S, Porszasz J, Ren SG, Da X, Casaburi R. Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol (1985). 2007 Oct;103(4):1299-310.
277. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998 Jun;83(6):1886-92.
278. Bondanelli M, Ambrosio MR, Margutti A, Franceschetti P, Zatelli MC, degli Uberti EC. Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone. Neuroendocrinology. 2003 Jun;77(6):380-7.
279. Veldhuis JD, Metzger DL, Martha PM Jr, Mauras N, Kerrigan JR, Keenan B, Rogol AD, Pincus SM. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab. 1997 Oct;82(10):3414-20.
280. Weissberger AJ, Ho KK. Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab. 1993 Jun;76(6):1407-12.
281. Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, Paulo R, Miles JM, Bowers CY. Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. J Clin Endocrinol Metab. 2009 Mar;94(3):973-81.
282. Yamamoto T, Sakai C, Yamaki J, Takamori K, Yoshiji S, Kitawaki J, Fujii M, Yasuda J, Honjo H, Okada H. Estrogen biosynthesis in human liver–a comparison of aromatase activity for C-19 steroids in fetal liver, adult liver and hepatoma tissues of human subjects. Endocrinol Jpn. 1984 Jun;31(3):277-81.
283. Hata S, Miki Y, Saito R, Ishida K, Watanabe M, Sasano H. Aromatase in human liver and its diseases. Cancer Med. 2013 Jun;2(3):305-15.
284. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med. 2003 Feb 13;348(7):618-29. Review. Erratum in: N Engl J Med. 2003 Mar 20;348(12):1192.
285. Löfgren L, Wallberg B, Wilking N, Fornander T, Rutqvist LE, Carlström K, von Schoultz B, von Schoultz E. Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. Med Oncol. 2004;21(4):309-18.
286. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab. 1993 Sep;77(3):776-9.
287. Centrella M, McCarthy TL, Chang WZ, Labaree DC, Hochberg RB. Estren (4-estren-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol Endocrinol. 2004 May;18(5):1120-30.
288. Yu YM, Domené HM, Sztein J, Counts DR, Cassorla F. Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Eur J Endocrinol. 1996 Nov;135(5):583-90.
289. Zung A, Phillip M, Chalew SA, Palese T, Kowarski AA, Zadik Z. Testosterone effect on growth and growth mediators of the GH-IGF-I axis in the liver and epiphyseal growth plate of juvenile rats. J Mol Endocrinol. 1999 Oct;23(2):209-21.
290. Hayes VY, Urban RJ, Jiang J, Marcell TJ, Helgeson K, Mauras N. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects. J Clin Endocrinol Metab. 2001 May;86(5):2211-9.
291. Sculthorpe N, Solomon AM, Sinanan AC, Bouloux PM, Grace F, Lewis MP. Androgens affect myogenesis in vitro and increase local IGF-1 expression. Med Sci Sports Exerc. 2012 Apr;44(4):610-5.
292. Birzniece V, Meinhardt UJ, Umpleby MA, Handelsman DJ, Ho KK. Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver. J Clin Endocrinol Metab. 2011 Apr;96(4):1060-7.
293. Mertani HC, Delehaye-Zervas MC, Martini JF, Postel-Vinay MC, Morel G. Localization of growth hormone receptor messenger RNA in human tissues. Endocrine. 1995 Feb;3(2):135-42.
294. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev. 1996 Oct;17(5):481-517. Review.
295. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995 Nov;269(5 Pt 1):E820-6.
296. Ewton DZ, Coolican SA, Mohan S, Chernausek SD, Florini JR. Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5: a dual role for IGFBP-5. J Cell Physiol. 1998 Oct;177(1):47-57.
297. Venken K, Movérare-Skrtic S, Kopchick JJ, Coschigano KT, Ohlsson C, Boonen S, Bouillon R, Vanderschueren D. Impact of androgens, growth hormone, and IGF-I on bone and muscle in male mice during puberty. J Bone Miner Res. 2007 Jan;22(1):72-82.
298. Serra C, Bhasin S, Tangherlini F, Barton ER, Ganno M, Zhang A, Shansky J, Vandenburgh HH, Travison TG, Jasuja R, Morris C. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology. 2011 Jan;152(1):193-206.
299. Spangenburg EE, Le Roith D, Ward CW, Bodine SC. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J Physiol. 2008 Jan 1;586(1):283-91.
300. Yoshizawa A, Clemmons DR. Testosterone and insulin-like growth factor (IGF) I interact in controlling IGF-binding protein production in androgen-responsive foreskin fibroblasts. J Clin Endocrinol Metab. 2000 Apr;85(4):1627-33.
301. Gayan-Ramirez G, Rollier H, Vanderhoydonc F, Verhoeven G, Gosselink R, Decramer M. Nandrolone decanoate does not enhance training effects but increases IGF-I mRNA in rat diaphragm. J Appl Physiol (1985). 2000 Jan;88(1):26-34.
302. Lewis MI, Horvitz GD, Clemmons DR, Fournier M. Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E483-90
303. Salmons S. Myotrophic effects of an anabolic steroid in rabbit limb muscles. Muscle Nerve. 1992 Jul;15(7):806-12.
304. Bisschop A, Gayan-Ramirez G, Rollier H, Dekhuijzen PN, Dom R, de Bock V, Decramer M. Effects of nandrolone decanoate on respiratory and peripheral muscles in male and female rats. J Appl Physiol (1985). 1997 Apr;82(4):1112-8
305. Lewis MI, Fournier M, Yeh AY, Micevych PE, Sieck GC. Alterations in diaphragm contractility after nandrolone administration: an analysis of potential mechanisms. J Appl Physiol (1985). 1999 Mar;86(3):985-92.
306. Heitzman RJ. The effectiveness of anabolic agents in increasing rate of growth in farm animals; report on experiments in cattle. Environ Qual Saf Suppl. 1976;(5):89-98. Review.
307. Buttery, P., Vernon, B., & Pearson, J. (1978). Anabolic agents—some thoughts on their mode of action. Proceedings of the Nutrition Society, 37(3), 311-315.
308. Hongerholt DD, Crooker BA, Wheaton JE, Carlson KM, Jorgenson DM. Effects of a growth hormone-releasing factor analogue and an estradiol-trenbolone acetate implant on somatotropin, insulin-like growth factor I, and metabolite profiles in growing Hereford steers. J Anim Sci. 1992 May;70(5):1439-48.
309. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism–towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009 Jun;72(6):723-8.
310. Kamanga-Sollo E, White ME, Hathaway MR, Weber WJ, Dayton WR. Effect of Estradiol-17beta on protein synthesis and degradation rates in fused bovine satellite cell cultures. Domest Anim Endocrinol. 2010 Jul;39(1):54-62.
311. Kamanga-Sollo E, Thornton KJ, White ME, Dayton WR. Role of G protein-coupled estrogen receptor-1, matrix metalloproteinases 2 and 9, and heparin binding epidermal growth factor-like growth factor in estradiol-17β-stimulated bovine satellite cell proliferation. Domest Anim Endocrinol. 2014 Oct;49:20-6.
312. Dunn JD, Johnson BJ, Kayser JP, Waylan AT, Sissom EK, Drouillard JS. Effects of flax supplementation and a combined trenbolone acetate and estradiol implant on circulating insulin-like growth factor-I and muscle insulin-like growth factor-I messenger RNA levels in beef cattle. J Anim Sci. 2003 Dec;81(12):3028-34.
313. Pampusch MS, Johnson BJ, White ME, Hathaway MR, Dunn JD, Waylan AT, Dayton WR. Time course of changes in growth factor mRNA levels in muscle of steroid-implanted and nonimplanted steers. J Anim Sci. 2003 Nov;81(11):2733-40.
314. Pampusch MS, White ME, Hathaway MR, Baxa TJ, Chung KY, Parr SL, Johnson BJ, Weber WJ, Dayton WR. Effects of implants of trenbolone acetate, estradiol, or both, on muscle insulin-like growth factor-I, insulin-like growth factor-I receptor, estrogen receptor-{alpha}, and androgen receptor messenger ribonucleic acid levels in feedlot steers. J Anim Sci. 2008 Dec;86(12):3418-23.
315. Thompson SH, Boxhorn LK, Kong WY, Allen RE. Trenbolone alters the responsiveness of skeletal muscle satellite cells to fibroblast growth factor and insulin-like growth factor I. Endocrinology. 1989 May;124(5):2110-7.
316. Johnson BJ, Halstead N, White ME, Hathaway MR, DiCostanzo A, Dayton WR. Activation state of muscle satellite cells isolated from steers implanted with a combined trenbolone acetate and estradiol implant. J Anim Sci. 1998 Nov;76(11):2779-86.
317. Dalbo VJ, Roberts MD, Mobley CB, Ballmann C, Kephart WC, Fox CD, Santucci VA, Conover CF, Beggs LA, Balaez A, Hoerr FJ, Yarrow JF, Borst SE, Beck DT. Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle. Andrologia. 2017 Apr;49(3).
318. Bhasin S, He EJ, Kawakubo M, Schroeder ET, Yarasheski K, Opiteck GJ, Reicin A, Chen F, Lam R, Tsou JA, Castaneda-Sceppa C, Binder EF, Azen SP, Sattler FR. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab. 2009 Nov;94(11):4224-33.
319. Nelson AE, Meinhardt U, Hansen JL, Walker IH, Stone G, Howe CJ, Leung KC, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab. 2008 Jun;93(6):2213-22.
320. Holt RI. Detecting growth hormone misuse in athletes. Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S18-22.
321. Tan SH, Lee A, Pascovici D, Care N, Birzniece V, Ho K, Molloy MP, Khan A. Plasma biomarker proteins for detection of human growth hormone administration in athletes. Sci Rep. 2017 Aug 30;7(1):10039.
322. Jørgensen JO, Jessen N, Pedersen SB, Vestergaard E, Gormsen L, Lund SA, Billestrup N. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E899-905.
323. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8831-5.
324. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 2008 Mar 15;22(6):711-21.
325. Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M. Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci. 1984 Jan;20(1):8-11.
326. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998 May 29;93(5):841-50.
327. Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005 Jul;90(7):4260-6. Epub 2005 Apr 12.
328. Rowland JE, Lichanska AM, Kerr LM, White M, d’Aniello EM, Maher SL, Brown R, Teasdale RD, Noakes PG, Waters MJ. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol. 2005 Jan;25(1):66-77. Erratum in: Mol Cell Biol. 2005 Mar;25(5):2072.
329. Klover P, Hennighausen L. Postnatal body growth is dependent on the transcription factors signal transducers and activators of transcription 5a/b in muscle: a role for autocrine/paracrine insulin-like growth factor I. Endocrinology. 2007 Apr;148(4):1489-97.
330. Barclay JL, Kerr LM, Arthur L, Rowland JE, Nelson CN, Ishikawa M, d’Aniello EM, White M, Noakes PG, Waters MJ. In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. Mol Endocrinol. 2010 Jan;24(1):204-17.
331. Hwa V, Nadeau K, Wit JM, Rosenfeld RG. STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):61-75.
332. Varco-Merth B, Feigerlová E, Shinde U, Rosenfeld RG, Hwa V, Rotwein P. Severe growth deficiency is associated with STAT5b mutations that disrupt protein folding and activity. Mol Endocrinol. 2013 Jan;27(1):150-61.
333. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology. 2001 Sep;142(9):3836-41.
334. Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003 Dec 19;278(51):51261-6. Epub 2003 Oct 7.
335. Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem. 2003 Jun 20;278(25):22696-702. Epub 2003 Apr 7.
336. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, McManus JF, Ma C, Plant DR, Lynch GS, Zajac JD. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J. 2008 Aug;22(8):2676-89.
337. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 2008 Jan 1;68(1):236-48.
338. Mathews LS, Norstedt G, Palmiter RD. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9343-7.
339. Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, Preiss R, Teichert J, Strasburger CJ, Bidlingmaier M. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur J Endocrinol. 2007 Jun;156(6):647-53.
340. Tanaka T, Seino Y, Fujieda K, Igarashi Y, Yokoya S, Tachibana K, Ogawa Y. Pharmacokinetics and metabolic effects of high-dose growth hormone administration in healthy adult men. Endocr J. 1999 Aug;46(4):605-12.
341. Quinn LS, Steinmetz B, Maas A, Ong L, Kaleko M. Type-1 insulin-like growth factor receptor overexpression produces dual effects on myoblast proliferation and differentiation. J Cell Physiol. 1994 Jun;159(3):387-98.
342. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem. 1997 Mar 7;272(10):6653-62.
343. Foulstone EJ, Huser C, Crown AL, Holly JM, Stewart CE. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: roles of IGF-I and TNFalpha. Exp Cell Res. 2004 Mar 10;294(1):223-35.
344. Ewton DZ, Roof SL, Magri KA, McWade FJ, Florini JR. IGF-II is more active than IGF-I in stimulating L6A1 myogenesis: greater mitogenic actions of IGF-I delay differentiation. J Cell Physiol. 1994 Nov;161(2):277-84.
345. Florini JR, Nicholson ML, Dulak NC. Effects of peptide anabolic hormones on growth of myoblasts in culture. Endocrinology. 1977 Jul;101(1):32-41.
346. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des. 2007;13(7):663-9. Review.
347. Jacquemin V, Furling D, Bigot A, Butler-Browne GS, Mouly V. IGF-1 induces human myotube hypertrophy by increasing cell recruitment. Exp Cell Res. 2004 Sep 10;299(1):148-58.
348. Jacquemin V, Butler-Browne GS, Furling D, Mouly V. IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes. J Cell Sci. 2007 Feb 15;120(Pt 4):670-81. Epub 2007 Jan 30.
349. Ballard FJ, Francis GL. Effects of anabolic agents on protein breakdown in L6 myoblasts. Biochem J. 1983 Jan 15;210(1):243-9.
350. Ewton DZ, Falen SL, Florini JR. The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-I analogs: pleiotypic actions of IGFs on myoblasts are apparently mediated by the type I receptor. Endocrinology. 1987 Jan;120(1):115-23.
351. Hembree JR, Hathaway MR, Dayton WR. Isolation and culture of fetal porcine myogenic cells and the effect of insulin, IGF-I, and sera on protein turnover in porcine myotube cultures. J Anim Sci. 1991 Aug;69(8):3241-50.
352. Hong D, Forsberg NE. Effects of serum and insulin-like growth factor I on protein degradation and protease gene expression in rat L8 myotubes. J Anim Sci. 1994 Sep;72(9):2279-88.
353. Florini JR, Ewton DZ, Roof SL. Insulin-like growth factor-I stimulates terminal myogenic differentiation by induction of myogenin gene expression. Mol Endocrinol. 1991 May;5(5):718-24.
354. Musarò A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 1999 Aug 5;400(6744):581-5.
355. Haba GDL, Cooper GW, Elting V. HORMONAL REQUIREMENTS FOR MYOGENESIS OF STRIATED MUSCLE IN VITRO: INSULIN AND SOMATOTROPIN. Proceedings of the National Academy of Sciences of the United States of America. 1966;56(6):1719-1723.
356. Florini JR, Ewton DZ. Insulin acts as a somatomedin analog in stimulating myoblast growth in serum-free medium. In Vitro. 1981 Sep;17(9):763-8.
357. Schmid C, Steiner T, Froesch ER. Preferential enhancement of myoblast differentiation by insulin-like growth factors (IGF I and IGF II) in primary cultures of chicken embryonic cells. FEBS Lett. 1983 Sep 5;161(1):117-21.
358. Florini JR, Ewton DZ, Falen SL, Van Wyk JJ. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol. 1986 May;250(5 Pt 1):C771-8.
359. Quinn LS, Ehsan M, Steinmetz B, Kaleko M. Ligand-dependent inhibition of myoblast differentiation by overexpression of the type-1 insulin-like growth factor receptor. J Cell Physiol. 1993 Sep;156(3):453-61.
360. Olson EN. Signal transduction pathways that regulate skeletal muscle gene expression. Mol Endocrinol. 1993 Nov;7(11):1369-78. Review.
361. Murphy LJ, Bell GI, Friesen HG. Growth hormone stimulates sequential induction of c-myc and insulin-like growth factor I expression in vivo. Endocrinology. 1987 May;120(5):1806-12.
362. Turner JD, Rotwein P, Novakofski J, Bechtel PJ. Induction of mRNA for IGF-I and -II during growth hormone-stimulated muscle hypertrophy. Am J Physiol. 1988 Oct;255(4 Pt 1):E513-7.
363. Isgaard J, Nilsson A, Vikman K, Isaksson OG. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J Endocrinol. 1989 Jan;120(1):107-12.
364. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol. 1992 Nov;6(11):1899-908.
365. Sadowski CL, Wheeler TT, Wang LH, Sadowski HB. GH regulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells. Endocrinology. 2001 Sep;142(9):3890-900.
366. Frost RA, Nystrom GJ, Lang CH. Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology. 2002 Feb;143(2):492-503.
367. MacLeod JN, Pampori NA, Shapiro BH. Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrinol. 1991 Dec;131(3):395-9.
368. Rochiccioli P, Messina A, Tauber MT, Enjaume C. Correlation of the parameters of 24-hour growth hormone secretion with growth velocity in 93 children of varying height. Horm Res. 1989;31(3):115-8.
369. Hansen TK, Gravholt CH, ØRskov H, Rasmussen MH, Christiansen JS, Jørgensen JO. Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab. 2002 Oct;87(10):4691-8.
370. Baum WF, Klöditz E, Hesse V, Jahreis G, Schneyer U, Giebler H. [Increase in spontaneous growth hormone secretion in asthmatic children–a symptom of atopic disposition?]. Kinderarztl Prax. 1993 Nov;61(9):323-8.
371. Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol (1985). 1998 May;84(5):1716-22.
372. Alzghoul MB, Gerrard D, Watkins BA, Hannon K. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB J. 2004 Jan;18(1):221-3. Epub 2003 Nov 3.
373. Lee S, Barton ER, Sweeney HL, Farrar RP. Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol (1985). 2004 Mar;96(3):1097-104. Erratum in: J Appl Physiol. 2004 Jun;96(6):2343.
374. Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995 May 19;270(20):12109-16.
375. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15603-7.
376. Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001 Feb;27(2):195-200
377. Lewis MI, Bulut Y, Biring MS, Da X, Fournier M. (1999) IGF-I administration prevents corticosteroids-induced diaphragm atrophy in emphysema . Am J Respir Crit Care Med 159:A580
378. Fournier M, Huang ZS, Cercek B, Li H, Bykhovskaya I, Lewis MI. (2000) Administration of insulin-like growth factor-1 (IGF-I) and corticosteroids in emphysematous hamsters: influences on diaphragm IGF-I . Am J Respir Crit Care Med 161:A18
379. Shavlakadze T, Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. Bioessays. 2006 Oct;28(10):994-1009. Review.
380. Maiter D, Underwood LE, Maes M, Davenport ML, Ketelslegers JM. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology. 1988 Aug;123(2):1053-9.
381. Isgaard J, Carlsson L, Isaksson OG, Jansson JO. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology. 1988 Dec;123(6):2605-10.
382. Clark RG, Jansson JO, Isaksson O, Robinson IC. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol. 1985 Jan;104(1):53-61.
383. Bick T, Hochberg Z, Amit T, Isaksson OG, Jansson JO. Roles of pulsatility and continuity of growth hormone (GH) administration in the regulation of hepatic GH-receptors, and circulating GH-binding protein and insulin-like growth factor-I. Endocrinology. 1992 Jul;131(1):423-9.
384. Weltman A, Weltman JY, Schurrer R, Evans WS, Veldhuis JD, Rogol AD. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. J Appl Physiol (1985). 1992 Jun;72(6):2188-96.
385. Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol Endocrinol. 2006 Feb;20(2):241-53. Epub 2005 Jul 21. Review.
386. Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth hormone secretion. Horm Res. 1993;40(1-3):37-47. Review.
387. Fernández L, Flores-Morales A, Lahuna O, Sliva D, Norstedt G, Haldosén LA, Mode A, Gustafsson JA. Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C. Endocrinology. 1998 Apr;139(4):1815-24.
388. Gebert CA, Park SH, Waxman DJ. Termination of growth hormone pulse-induced STAT5b signaling. Mol Endocrinol. 1999 Jan;13(1):38-56.
389. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem. 1999 Dec 10;274(50):35553-61.
390. Ram PA, Waxman DJ. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem.2000 Dec 15;275(50):39487-96.
391. Xu J, Keeton AB, Franklin JL, Li X, Venable DY, Frank SJ, Messina JL. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J Biol Chem. 2006 Jan 13;281(2):982-92. Epub 2005 Nov 4.
392. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139. Review.
393. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol. 1999;71(3-4):479-500. Review.
394. Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D’Hoore A, Darras VM, Visser TJ, Van den Berghe G. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol. 2009 Aug;161(2):243-50.
395. Jørgensen JO, Pedersen SA, Laurberg P, Weeke J, Skakkebaek NE, Christiansen JS. Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J Clin Endocrinol Metab. 1989 Dec;69(6):1127-32.
396. Jørgensen JO, Pedersen SB, Børglum J, Møller N, Schmitz O, Christiansen JS, Richelsen B. Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: a double-blind placebo-controlled study. Metabolism. 1994 Jul;43(7):872-7.
397. Wolthers T, Grøftne T, Møller N, Christiansen JS, Orskov H, Weeke J, Jørgensen JO. Calorigenic effects of growth hormone: the role of thyroid hormones. J Clin Endocrinol Metab. 1996 Apr;81(4):1416-9.
398. Feldt-Rasmussen U. Interactions between growth hormone and the thyroid gland — with special reference to biochemical diagnosis. Curr Med Chem. 2007;14(26):2783-8. Review.
399. Kalina-Faska B, Kalina M, Koehler B. Effects of recombinant growth hormone therapy on thyroid hormone concentrations. Int J Clin Pharmacol Ther. 2004 Jan;42(1):30-4.
400. Hubina E, Mersebach H, Rasmussen AK, Juul A, Sneppen SB, Góth MI, Feldt-Rasmussen U. Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults. Horm Res. 2004;61(5):211-7. Epub 2004 Jan 30.
401. Seminara S, Stagi S, Candura L, Scrivano M, Lenzi L, Nanni L, Pagliai F, Chiarelli F. Changes of thyroid function during long-term hGH therapy in GHD children. A possible relationship with catch-up growth? Horm Metab Res. 2005 Dec;37(12):751-6.
402. Losa M, Scavini M, Gatti E, Rossini A, Madaschi S, Formenti I, Caumo A, Stidley CA, Lanzi R. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid. 2008 Dec;18(12):1249-54.
403. Müller MJ, Seitz HJ. Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism. Klin Wochenschr. 1984 Feb 1;62(3):97-102.
404. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest. 1997 Jul 1;100(1):197-203. PubMed PMID: 9202072
405. Dace A, Zhao L, Park KS, et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(16):8985-8990.
406. Clément K, Viguerie N, Diehn M, Alizadeh A, Barbe P, Thalamas C, Storey JD, Brown PO, Barsh GS, Langin D. In vivo regulation of human skeletal muscle gene expression by thyroid hormone. Genome Res. 2002 Feb;12(2):281-91.
407. Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab. 1993 Apr;76(4):950-5.
408. Murao K, Takahara J, Sato M, Tamaki M, Niimi M, Ishida T. Relationship between thyroid functions and urinary growth hormone secretion in patients with hyper- and hypothyroidism. Endocr J. 1994 Oct;41(5):517-22.
409. Wolf M, Ingbar SH, Moses AC. Thyroid hormone and growth hormone interact to regulate insulin-like growth factor-I messenger ribonucleic acid and circulating levels in the rat. Endocrinology. 1989 Dec;125(6):2905-14.
410. Laron Z. Interactions between the thyroid hormones and the hormones of the growth hormone axis. Pediatr Endocrinol Rev. 2003 Dec;1 Suppl 2:244-9-discussion 250. Review.
411. Fiems LO. Double Muscling in Cattle: Genes, Husbandry, Carcasses and Meat. Animals : an Open Access Journal from MDPI. 2012;2(3):472-506.
412. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002 Dec 20;277(51):49831-40. Epub 2002 Sep 18.
413. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12457-61.
414. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF, Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004 Jun 24;350(26):2682-8.
415. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibé B, Bouix J, Caiment F, Elsen JM, Eychenne F, Larzul C, Laville E, Meish F, Milenkovic D, Tobin J, Charlier C, Georges M. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006 Jul;38(7):813-8.
416. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14938-43.
417. Liu W, Thomas SG, Asa SL, Gonzalez-Cadavid N, Bhasin S, Ezzat S. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab. 2003 Nov;88(11):5490-6.
418. Oldham JM, Osepchook CC, Jeanplong F, Falconer SJ, Matthews KG, Conaglen JV, Gerrard DF, Smith HK, Wilkins RJ, Bass JJ, McMahon CD. The decrease in mature myostatin protein in male skeletal muscle is developmentally regulated by growth hormone. J Physiol. 2009 Feb 1;587(3):669-77.
419. Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P, Rodgers BD. Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis. Endocrinology. 2011 Jan;152(1):172-80.
420. Winbanks CE, Weeks KL, Thomson RE, Sepulveda PV, Beyer C, Qian H, Chen JL, Allen JM, Lancaster GI, Febbraio MA, Harrison CA, McMullen JR, Chamberlain JS, Gregorevic P. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J Cell Biol. 2012 Jun 25;197(7):997-1008.
421. Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, Hatakeyama S, Glass DJ. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18.
422. Bark TH, McNurlan MA, Lang CH, Garlick PJ. Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am J Physiol. 1998 Jul;275(1 Pt 1):E118-23.
423. Barton-Davis ER, Shoturma DI, Sweeney HL. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand. 1999 Dec;167(4):301-5.
424. Suryawan A, Frank JW, Nguyen HV, Davis TA. Expression of the TGF-beta family of ligands is developmentally regulated in skeletal muscle of neonatal rats. Pediatr Res. 2006 Feb;59(2):175-9.
425. Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E157-64.
426. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001 Nov;3(11):1014-9.
427. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001 Nov;3(11):1009-13.
428. Kalista S, Schakman O, Gilson H, Lause P, Demeulder B, Bertrand L, Pende M, Thissen JP. The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy. Endocrinology. 2012 Jan;153(1):241-53.
429. Barbé C, Kalista S, Loumaye A, Ritvos O, Lause P, Ferracin B, Thissen JP. Role of IGF-I in follistatin-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab. 2015 Sep 15;309(6):E557-67. doi: 10.1152/ajpendo.00098.2015. Epub 2015 Jul 28.
430. Coffey VG, Shield A, Canny BJ, Carey KA, Cameron-Smith D, Hawley JA. Interaction of contractile activity and training history on mRNA abundance in skeletal muscle from trained athletes. Am J Physiol Endocrinol Metab. 2006 May;290(5):E849-55.
431. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab. 1980 Oct;51(4):691-7
432. Dannies PS. Protein folding and deficiencies caused by dominant-negative mutants of hormones. Vitam Horm. 2000;58:1-26. Review.
433. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol. 1990 Jul;259(1 Pt 1):E89-95.
434. Hermansen K, Bengtsen M, Kjær M, Vestergaard P, Jørgensen JOL. Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res. 2017 Jun;34:38-44.
435. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011 Dec;108(11):1860-5.
436. Kraemer WJ, Marchitelli L, Gordon SE, Harman E, Dziados JE, Mello R, Frykman P, McCurry D, Fleck SJ. Hormonal and growth factor responses to heavy resistance exercise protocols. J Appl Physiol (1985). 1990 Oct;69(4):1442-50.
437. Pfeffer LA, Brisson BK, Lei H, Barton ER. The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell. 2009 Sep;20(17):3810-7.
438. Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007 Oct;7(10):2247-59.
439. Brisson BK, Barton ER. Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor. PLoS One. 2012;7(9):e45588.
440. Brisson BK, Spinazzola J, Park S, Barton ER. Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength. Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E965-74.
441. Goldspink G, Harridge S. Mechanism for adaptation in skeletal muscle In: Komi P, editor. Strength and power in sport: Olympic encyclopedia of sports medicine. Oxford: Blackwell; 2002. p. 231–51.
442. Janssen JA, Hofland LJ, Strasburger CJ, van den Dungen ES, Thevis M. Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS One. 2016 Mar 18;11(3):e0150453.
About the author
Chester “Chest” Rockwell is head coach of TeamStackingPlates (TSP). For more information on the team, coaching inquiries, as well as more articles, please visit the team website.
45 replies
Loading new replies...
Join the full discussion at the MESO-Rx →